Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Idarubicin hydrochloride
Drug ID BADD_D01128
Description An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Indications and Usage For the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7.
Marketing Status approved
ATC Code L01DB06
DrugBank ID DB01177
KEGG ID D01747
MeSH ID D015255
PubChem ID 636362
TTD Drug ID D01XDL
NDC Product Code 77391-003; 58623-0027; 0143-9308; 0013-2576; 0013-2596; 0703-4156; 17337-0098; 0143-9218; 0703-4155; 0143-9219; 0143-9306; 0143-9307; 0143-9217; 0013-2586
UNII 5VV3MDU5IE
Synonyms Idarubicin | 4-Desmethoxydaunorubicin | 4 Desmethoxydaunorubicin | 4-Demethoxydaunorubicin | 4 Demethoxydaunorubicin | IMI-30 | IMI 30 | IMI30 | NSC-256439 | NSC 256439 | NSC256439 | Idarubicin Hydrochloride | Hydrochloride, Idarubicin
Chemical Information
Molecular Formula C26H28ClNO9
CAS Registry Number 57852-57-0
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal pain07.01.05.002--
Alopecia23.02.02.001--
Anaemia01.03.02.001--
Aplasia03.02.01.002; 08.03.04.003---
Arrhythmia02.03.02.001---
Atrial fibrillation02.03.03.002--
Body temperature increased13.15.01.001---
Cardiac failure congestive02.05.01.002---
Cerebellar syndrome17.02.02.002---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Dermatitis23.03.04.002---
Dermatitis bullous23.03.01.002--
Diarrhoea07.02.01.001--
Enterocolitis07.08.03.003--
Gastrointestinal pain07.01.05.005--
Haemoglobin13.01.05.018---
Headache17.14.01.001--
Hypersensitivity10.01.03.003--
Hypervolaemia02.05.04.019; 14.05.06.003---
Infection11.01.08.002---
Injection site urticaria08.02.03.029; 10.01.06.003; 12.07.03.029; 23.04.02.003---
Local reaction08.01.03.012---
Lung disorder22.02.07.001---
Mucosal inflammation08.01.06.002---
Myocardial infarction02.02.02.007; 24.04.04.009--
Nausea07.01.07.001--
Neuropathy peripheral17.09.03.003---
Pancytopenia01.03.03.003---
Pyrexia08.05.02.003--
The 1th Page    1 2    Next   Last    Total 2 Pages